Cargando…
An experimental medicine study of the phosphodiesterase-4 inhibitor, roflumilast, on working memory-related brain activity and episodic memory in schizophrenia patients
RATIONALE: Schizophrenia is associated with impairments in cognitive functioning yet there are no approved drugs to treat these deficits. OBJECTIVES: Based on animal models, we investigated the potential for roflumilast, a selective inhibitor of phosphodiesterase type 4 (PDE4), to improve cognition,...
Autores principales: | Gilleen, James, Farah, Yakub, Davison, Cate, Kerins, Sarah, Valdearenas, Lorena, Uz, Tolga, Lahu, Gez, Tsai, Max, Ogrinc, Frank, Reichenberg, Avi, Williams, Steve C., Mehta, Mitul A., Shergill, Sukhi S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8062361/ https://www.ncbi.nlm.nih.gov/pubmed/30536081 http://dx.doi.org/10.1007/s00213-018-5134-y |
Ejemplares similares
-
Preliminary evidence for the phosphodiesterase type-4 inhibitor, roflumilast, in ameliorating cognitive flexibility deficits in patients with schizophrenia
por: Livingston, Nicholas R, et al.
Publicado: (2021) -
Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD
por: Giembycz, Mark A, et al.
Publicado: (2010) -
Roflumilast, a Novel Phosphodiesterase 4 Inhibitor, for COPD Patients with a History of Exacerbations
por: Field, Stephen K.
Publicado: (2011) -
Roflumilast, a phosphodiesterase-4 inhibitor, induces phagocytic activity in Greek COPD patients
por: Porpodis, Konstantinos, et al.
Publicado: (2015) -
Characterization of Resveratrol, Oxyresveratrol, Piceatannol and Roflumilast as Modulators of Phosphodiesterase Activity. Study of Yeast Lifespan
por: Matencio, Adrián, et al.
Publicado: (2020)